Skip to content
The Nexus
DossierENTITY

VERV-102

Coverage of VERV-102 in the Nexus archive.

Earliest in view: May 25 · 12:45 UTCMost recent: May 25 · 12:45 UTC
Co-mentioned in this coverage
Eli Lillyorganization1Verve Therapeuticsorganization1LDL cholesteroltopic1Phase 1 studytopic1heart diseasetopic1gene-editing therapytopic1
Recent coverage
  • HEALTHMay 25 · 12:45 UTCSTAT NEWS
    STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

    Eli Lilly reported a 62% reduction in LDL cholesterol levels in a Phase 1 trial using its gene-editing therapy, VERV-102, acquired from Verve Therapeutics. The therapy showed no serious adverse events, marking a significant safety improvement over Verve's previous shelved candidate. The treatment is positioned as a potential one-time solution for preventing heart disease.